The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The prognostic value of MRD in patients with AML treated with venetoclax plus HMA
Carlos Jimenez-Vicente, MD, Hospital Clinic Barcelona, Barcelona, Spain, comments on the prognostic value of measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) who have received treatment with venetoclax in combination with hypomethylating agents (HMA). Dr Jimenez-Vicente highlights that MRD is a significant prognostic indicator for overall survival and leukemia-free survival, and independently predicts outcome regardless of the MRD detection technique used. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So what we’ve performed is a retrospective study of initially 278 patients that were treated with venetoclax in combination with hypomethylating agents. And afterwards we selected the responders, the patients that had achieved a morphological response that had at least been treated with two cycles of treatment in order to analyse the paper and the value of MRD as a prognostic value for overall survival...
So what we’ve performed is a retrospective study of initially 278 patients that were treated with venetoclax in combination with hypomethylating agents. And afterwards we selected the responders, the patients that had achieved a morphological response that had at least been treated with two cycles of treatment in order to analyse the paper and the value of MRD as a prognostic value for overall survival. What we observed is that according to the ELN 2021 MRD recommendations which are the standard or the most used for patients undergoing chemotherapy, these recommendations also show us a prognostic value of MRD for overall survival in patients treated with venetoclax in combination with hypomethylating agents. This was also prognostic for leukemia-free survival and really interestingly independently of the technique that we used, MRD based on quantitative PCR or flow cytometry. It was significant in both cases such as other studies have shown but it was even more significant when we combined all techniques together based on the Mantel-Byar test and that’s pretty much what we performed.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie: Other: Travel Grants; AbbVie: Speakers Bureau.
